The ZosterFluCOV study is a collaboration between the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust and it is being run by the Bristol Trials Centre. The study is looking at the safety, as well as the immune responses, when giving the currently approved shingles vaccine (Shingrix) at the same time as either the recommended COVID-19 booster or the influenza (flu) vaccines from the 2023/2024 flu season programme.
This study is Sponsored by University Hospitals Bristol and Weston NHS Foundation Trust (Chief Investigator Dr Rajeka Lazarus). The study is funded by GlaxoSmithKline Ltd (GSK).
It is intended that the results of this study will be used to inform UK immunisation policy.